• Agius L, Peak M, Newgard CB, Gomez-Foix AM, Guinovart JJ (1996). Evidence for a role of glucose induced translocation of glucokinase in the control of hepaic glycogen synthesis. J Biol Chem 271: 3047930486.
  • Basu R, Basu A, Johnson CM, Schwenk WF, Rizza RA (2004). Insulin dose–response curves for stimulation of splanchnic glucose uptake and suppression of endogenous glucose production differ in nondiabetic humans and are abnormal in people with type 2 diabetes. Diabetes 53: 20422050.
  • Brocklehurst KJ, Payne VA, Davies RA, Carroll D, Vertigan HL, Wightman HJ et al. (2004). Stimulation of hepatocyte glucose metabolism by novel small molecule glucokinase activators. Diabetes 53: 535541.
  • Cuesta-Muñoz AL, Huopio H, Otonkoski T, Gomez-Zumaquero JM, Näntö-Salonen K, Rahier J et al. (2004). Severe persistent hyperinsulinemic hypoglycemia due to a de novo glucokinase mutation. Diabetes 53: 21642168.
  • Efanov AM, Barrett DG, Brenner MB, Briggs SL, Delaunois A, Durbin JD et al. (2005). A novel glucokinase activator modulates pancreatic islet and hepatocyte function. Endocrinology 146: 36963701.
  • Etgen GJ, Oldham BA, Johnson WT, Broderick CL, Montrose CR, Brozinick JT et al. (2002). A Tailored therapy for the metabolic syndrome. The dual peroxisomal proliferator-activated receptor-α/γ agonist LY465608 ameliorates insulin resistance and diabetic hyperglycaemia while improving cardiovascular risk factors in preclinical models. Diabetes 51: 10831087.
  • Grimsby J, Sarabu R, Corbett WL, Haynes NE, Bizzarro FT, Coffey JW et al. (2003). Allosteric activation of glucokinase: potential role in diabetes therapy. Science 301: 370373.
  • Kamata K, Mitsuya M, Nishimura T, Eiki JI, Nagata Y (2004). Structural basis for allosteric activation of the monomeric enzyme human glucokinase. Structure 12: 429438.
  • Leighton B, Atkinson A, Coghlan MP (2005). Small molecule glucokinase activators as novel anti-diabetic agents. Biochem Soc Trans 33: 371374.
  • Matchinsky FM (2005). Glucokinase, glucose homeostasis, and diabetes mellitus. Curr Diab Rep 5: 171176.
  • Matschinsky FM, Magnusen MA (2004). Glucokinase and glycemic disease: from basics to novel therapeutics. Front Diabetes 16: 4264.
  • McKerrecher D, Allen JV, Bowker SS, Boyd S, Caulkett PWR, Currie GS et al. (2005). Discovery, synthesis and biological evaluation of novel glucokinase activators. Bioorganic Med Chem Lett 15: 21032106.
  • McKerrecher D, Allen JV, Donald CS, Fenwick ML, Grange E, Johnson KM et al. (2006). Design of a potent, soluble glucokinase activator with excellent in vivo efficacy. Bioorganic Med Chem Lett 16: 27052709.
  • Meglasson MD, Matschinsky FM (1986). Pancreatic islet glucose metabolism and regulation of insulin secretion. Diabetes Metab Res Rev 2: 163214.
  • Obeid OA, Powell-Tuck J, Emery PW (2000). The postprandial rates of glycogen and lipid synthesis of lean and obese female Zucker rats. Int J Obes Relat Metab Disord 24: 508513.
  • Oravcova J, Böhs B, Linder W (1996). Drug protein binding studies new trends in analytical and experimental methodology. J Chromatogr B 677: 128.
  • Pan SJ, Hancock J, Ding Z, Fogt D, Lee M, Ivy JL (2001). Effects of clembuterol on insulin resistance in conscious obese Zucker rats. Am J Physiol 280: E554E561.
  • Sarabu R, Grimsby J (2005). Targetting glucokinase activation for the treatment of type 2 diabetes – a status review. Curr Opin Drug Discov Dev 8: 631637.
  • Stokes WS, Schechtman LM, Hill RN (2002). The Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM): a review of the ICCVAM test method evaluation process and current international collaborations with the European Centre for the Validation of Alternative Methods (ECVAM). Alternative Lab Animal 30 (Suppl 2), 2332.
  • Velho G, Falk K, Pereseghin G, Hwang JH, Rothman DL, Pueyo ME et al. (1996). Impaired hepatic glycogen synthesis in glucokinase-deficient (MODY-2) subjects. J Clin Invest 98: 17551761.
  • Xu BX, Berkich DA, Crist GH, Lanoue KF (1998). A1 adenosine receptor antagonism improves glucose tolerance in Zucker rats. Am J Physiol 274: E271E279.
  • Xu J (2004). Current and emerging therapies for type 2 diabetes. IDrugs 7: 249256.
  • Zimmet P, Shaw J, Alberti GMM (2003). Preventing type 2 diabetes and the dysmetabolic syndrome in the real world: a realistic view. Diabet Med 20: 693702.